Search
Pancreatic Cancer Paid Clinical Trials in New York
A listing of 41 Pancreatic Cancer clinical trials in New York actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 41
The state of New York currently has 41 active clinical trials seeking participants for Pancreatic Cancer research studies. These trials are conducted in various cities, including New York, Rochester, Bronx and Buffalo.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Featured Trial
Chronic Kidney Disease (CKD) Clinical Study
Recruiting
A clinical study for people that suffer with Chronic Kidney Disease (CKD)
Conditions:
Chronic Kidney Disease (CKD)
Featured Trial
Ischemic heart disease (IHD) Clinical Study
Recruiting
A clinical study for people that suffer with Ischemic heart disease (IHD)
Conditions:
Ischemic heart disease (IHD)
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
Recruiting
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York +1 locations
Conditions: Stage IV Pancreatic Cancer AJCC v8, Metastatic Pancreatic Adenocarcinoma
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Recruiting
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/19/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
Recruiting
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York +4 locations
Conditions: Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Exocrine Pancreas Carcinoma
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
Recruiting
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic cancer in patients who have a deleterious or suspected deleterious BRCA1, BRCA2, or PALB2 genetic alteration. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, low-dose I.V. ethanol, vitamin B12b, and vitamin C in association with autologous hematopoietic stem cell infusion. A dose-escalation schedule will be employed fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Breast Cancer Metastatic, Breast Cancer Stage IV, Pancreatic Cancer Stage IV, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Adenocarcinoma of the Breast, PALB2 Gene Mutation
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Recruiting
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York +2 locations
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Recruiting
The purpose of this study is to find out how effective and safe glipizide is for lowering blood sugar in people with pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities), Commack, New York +3 locations
Conditions: Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Metastatic, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
Recruiting
This is a multi-center clinical study enrolling up to 30 participants (15 patients in each cohort). The primary objective of the study is to evaluate the safety of Alpha DaRT in combination with chemotherapy, based on the cumulative incidence rate, severity and outcome of device related AEs. Classification of AEs will be done according to CTCAE V5. The secondary objectives of the study are to:
* Assess efficacy of the Alpha DaRT sources in combination with chemotherapy, determined by overall an... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/13/2025
Locations: Montefiore Medical Center, Bronx, New York +3 locations
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
Recruiting
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: NYU Langone Hospital - Long Island, Mineola, New York +2 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Recruiting
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Montefiore Medical Center-Einstein Campus, Bronx, New York +5 locations
Conditions: Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Recruiting
Genetic testing is a type of test that detects changes to the genes-the DNA instructions that are passed on from the mother and father. The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Genetic testing can also help determine a person's chance of getting or passing on a genetic disorder. Genetic tests use a sample of blood, hair, skin, or other tissue, and they can look at one gene or m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Kings County Hopsital Center, Brooklyn, New York +3 locations
Conditions: Educational Materials for Genetic Testing, Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Recruiting
The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Cold Springs Harbor Laboratory (Specimen Analysis), Cold Spring Harbor, New York +7 locations
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Recruiting
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or RMC-9805. The study comprises a dose escalation phase and a dose expansion phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: NYU Langone Health, New York, New York
Conditions: PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
1 - 12 of 41